Overview
Uplizna is approved by the U.S. Food and Drug Administration (FDA) for the treatment of generalized myasthenia gravis (gMG) in adults who test positive for anti-acetylcholine receptor (AChR) or anti-muscle specific tyrosine kinase (MuSK) antibodies. It is prescribed only for antibody-positive adults with gMG. Uplizna is also known by its drug name, inebilizumab-cdon.

Uplizna is a CD19-directed cytolytic antibody. Scientists believe it works by targeting and reducing specific B cells, a type of immune cell involved in the autoimmune attack on communication between nerves and muscles that causes gMG symptoms.

How do I take it?

Prescribing information states that Uplizna is given as an intravenous (IV) infusion. The initial treatment typically consists of two infusions given two weeks apart. After that, a single infusion is typically administered every six months. The infusion takes about 90 minutes, and individuals are monitored for at least one hour afterward. The drug should be administered exactly as prescribed by a healt care provider.

Side effects
Common side effects of Uplizna include headache and infusion-related reactions.

Rare but serious side effects may include severe infusion reactions, serious or fatal infections, decreased immunoglobulin levels (which can increase infection risk), and fetal harm if used during pregnancy.

For more information about this treatment, visit:
Uplizna (Inebilizumab-Cdon) Injection, for Intravenous Use — Amgen